Log in
Sign Up. It's Free
Home
Trulicity®
Interactions
Drugs interactions for Trulicity®
Check individual interactions
0 Major drug
interactions
257 Moderate drug
interactions (including ingredients like Acarbose, Acebutolol, Acetylsalicylic acid)
188 Minor drug
interactions (including ingredients like Acetazolamide, Acetyl sulfisoxazole, Adalimumab)
445 interactions for Trulicity®
Sort by
All drug interactions
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Trulicity®.
Acarbose
The risk or severity of hypoglycemia can be increased when Acarbose is combined with Dulaglutide.
Acebutolol
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Acebutolol.
Acetylsalicylic acid
The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Dulaglutide.
Alclometasone
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Dulaglutide.
Alogliptin
The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Dulaglutide.
Amcinonide
The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Dulaglutide.
Aminosalicylic acid
Aminosalicylic acid may increase the hypoglycemic activities of Dulaglutide.
Amiodarone
The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Dulaglutide.
Amitriptyline
Amitriptyline may decrease the hypoglycemic activities of Dulaglutide.
Amlodipine
The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Dulaglutide.
Amoxapine
Amoxapine may decrease the hypoglycemic activities of Dulaglutide.
Aripiprazole
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Aripiprazole.
Arsenic trioxide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Arsenic trioxide.
Articaine
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Articaine.
Asenapine
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Asenapine.
Atazanavir
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Atazanavir.
Atenolol
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Atenolol.
Baclofen
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Baclofen.
Balsalazide
Balsalazide may increase the hypoglycemic activities of Dulaglutide.
Beclomethasone dipropionate
The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Dulaglutide.
Benazepril
The risk or severity of hypoglycemia can be increased when Benazepril is combined with Dulaglutide.
Bendroflumethiazide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Bendroflumethiazide.
Betamethasone
The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Dulaglutide.
Betaxolol
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Betaxolol.
Bexagliflozin
Bexagliflozin may increase the hypoglycemic activities of Dulaglutide.
Bismuth subsalicylate
Bismuth subsalicylate may increase the hypoglycemic activities of Dulaglutide.
Bisoprolol
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Bisoprolol.
Brexpiprazole
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Brexpiprazole.
Bromocriptine
The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Dulaglutide.
Budesonide
The risk or severity of hyperglycemia can be increased when Budesonide is combined with Dulaglutide.
Bumetanide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Bumetanide.
Canagliflozin
Canagliflozin may increase the hypoglycemic activities of Dulaglutide.
Carvedilol
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Carvedilol.
Ceritinib
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ceritinib.
Chlorothiazide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Chlorothiazide.
Chlorpromazine
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Chlorpromazine.
Chlorthalidone
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Chlorthalidone.
Choline salicylate
Choline salicylate may increase the hypoglycemic activities of Dulaglutide.
Ciclesonide
The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Dulaglutide.
Ciprofloxacin
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Ciprofloxacin.
Citalopram
The risk or severity of hypoglycemia can be increased when Citalopram is combined with Dulaglutide.
Clevidipine
The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Dulaglutide.
Clobetasol propionate
The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Dulaglutide.
Clocortolone
The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Dulaglutide.
Clomipramine
Clomipramine may decrease the hypoglycemic activities of Dulaglutide.
Clozapine
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Clozapine.
Conjugated estrogens
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Conjugated estrogens.
Corticotropin
The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Dulaglutide.
Cortisone acetate
The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Dulaglutide.
Dabrafenib
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Dabrafenib.
Danazol
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Danazol.
Dapagliflozin
Dapagliflozin may increase the hypoglycemic activities of Dulaglutide.
Darunavir
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Darunavir.
Deflazacort
The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Dulaglutide.
Delafloxacin
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Delafloxacin.
Desipramine
Desipramine may decrease the hypoglycemic activities of Dulaglutide.
Desogestrel
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Desogestrel.
Desonide
The risk or severity of hyperglycemia can be increased when Desonide is combined with Dulaglutide.
Desoximetasone
The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Dulaglutide.
Desvenlafaxine
The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Dulaglutide.
Dexamethasone
The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Dulaglutide.
Dexamethasone acetate
The risk or severity of hyperglycemia can be increased when Dexamethasone acetate is combined with Dulaglutide.
Diazoxide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Diazoxide.
Dienogest
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Dienogest.
Diflorasone
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Dulaglutide.
Diflunisal
Diflunisal may increase the hypoglycemic activities of Dulaglutide.
Difluprednate
The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Dulaglutide.
Diltiazem
The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Dulaglutide.
Disopyramide
The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Dulaglutide.
Doxepin
Doxepin may decrease the hypoglycemic activities of Dulaglutide.
Drospirenone
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Drospirenone.
Duloxetine
The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Dulaglutide.
Empagliflozin
Empagliflozin may increase the hypoglycemic activities of Dulaglutide.
Epinephrine
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Epinephrine.
Ertugliflozin
Ertugliflozin may increase the hypoglycemic activities of Dulaglutide.
Escitalopram
The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Dulaglutide.
Estetrol
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Estetrol.
Estradiol
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Estradiol.
Estrone sulfate
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Estrone sulfate.
Etacrynic acid
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Etacrynic acid.
Ethinylestradiol
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ethinylestradiol.
Ethosuximide
The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Dulaglutide.
Ethynodiol diacetate
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ethynodiol diacetate.
Etonogestrel
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Etonogestrel.
Everolimus
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Everolimus.
Exenatide
The risk or severity of hypoglycemia can be increased when Exenatide is combined with Dulaglutide.
Felodipine
The risk or severity of hypoglycemia can be increased when Felodipine is combined with Dulaglutide.
Fluconazole
The risk or severity of hypoglycemia can be increased when Dulaglutide is combined with Fluconazole.
Fludrocortisone
The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Dulaglutide.
Flunisolide
The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Dulaglutide.
Fluocinolone acetonide
The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Dulaglutide.
Fluocinonide
The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Dulaglutide.
Fluorometholone
The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Dulaglutide.
Fluoxetine
The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Dulaglutide.
Flurandrenolide
The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Dulaglutide.
Fluticasone furoate
The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Dulaglutide.
Fluticasone propionate
The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Dulaglutide.
Fluvoxamine
The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Dulaglutide.
Fosamprenavir
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Fosamprenavir.
Furosemide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Furosemide.
Gatifloxacin
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Gatifloxacin.
Gemifloxacin
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Gemifloxacin.
Glimepiride
Dulaglutide may increase the hypoglycemic activities of Glimepiride.
Glipizide
Dulaglutide may increase the hypoglycemic activities of Glipizide.
Glyburide
Dulaglutide may increase the hypoglycemic activities of Glyburide.
Goserelin
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Goserelin.
Halcinonide
The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Dulaglutide.
Haloperidol
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Haloperidol.
Histrelin
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Histrelin.
Hydrochlorothiazide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Hydrochlorothiazide.
Hydrocortisone
The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Dulaglutide.
Hydrocortisone acetate
The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Dulaglutide.
Hydrocortisone butyrate
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Dulaglutide.
Hydrocortisone probutate
The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Dulaglutide.
Hydrocortisone succinate
The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Dulaglutide.
Hydrocortisone valerate
The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Dulaglutide.
Hydroflumethiazide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Hydroflumethiazide.
Hydroxychloroquine
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Hydroxychloroquine.
Hydroxyprogesterone caproate
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Hydroxyprogesterone caproate.
Iloperidone
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Iloperidone.
Imipramine
Imipramine may decrease the hypoglycemic activities of Dulaglutide.
Indapamide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Indapamide.
Indinavir
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Indinavir.
Indomethacin
The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Dulaglutide.
Insulin aspart
The risk or severity of hypoglycemia can be increased when Dulaglutide is combined with Insulin aspart.
Insulin degludec
The risk or severity of hypoglycemia can be increased when Dulaglutide is combined with Insulin degludec.
Insulin detemir
The risk or severity of hypoglycemia can be increased when Dulaglutide is combined with Insulin detemir.
Insulin glargine
The risk or severity of hypoglycemia can be increased when Dulaglutide is combined with Insulin glargine.
Insulin glulisine
The risk or severity of hypoglycemia can be increased when Dulaglutide is combined with Insulin glulisine.
Insulin human
The risk or severity of hypoglycemia can be increased when Dulaglutide is combined with Insulin human.
Insulin lispro
The risk or severity of hypoglycemia can be increased when Dulaglutide is combined with Insulin lispro.
Isoniazid
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Isoniazid.
Isradipine
The risk or severity of hypoglycemia can be increased when Isradipine is combined with Dulaglutide.
Labetalol
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Labetalol.
Lanreotide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lanreotide.
Leuprolide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Leuprolide.
Levamlodipine
The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Dulaglutide.
Levofloxacin
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Levofloxacin.
Levomilnacipran
The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Dulaglutide.
Levonorgestrel
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Levonorgestrel.
Linagliptin
The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Dulaglutide.
Liothyronine
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Liothyronine.
Lipoic acid
The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Dulaglutide.
Liraglutide
The risk or severity of hypoglycemia can be increased when Liraglutide is combined with Dulaglutide.
Lixisenatide
The risk or severity of hypoglycemia can be increased when Dulaglutide is combined with Lixisenatide.
Lomefloxacin
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Lomefloxacin.
Lonapegsomatropin
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lonapegsomatropin.
Lopinavir
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lopinavir.
Lurasidone
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lurasidone.
Magnesium sulfate
The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Dulaglutide.
Mecasermin
The risk or severity of hypoglycemia can be increased when Mecasermin is combined with Dulaglutide.
Medroxyprogesterone acetate
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Medroxyprogesterone acetate.
Medrysone
The risk or severity of hyperglycemia can be increased when Medrysone is combined with Dulaglutide.
Megestrol acetate
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Megestrol acetate.
Mesalazine
Mesalazine may increase the hypoglycemic activities of Dulaglutide.
Metformin
The risk or severity of hypoglycemia can be increased when Metformin is combined with Dulaglutide.
Methsuximide
The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Dulaglutide.
Methyl salicylate
Methyl salicylate may increase the hypoglycemic activities of Dulaglutide.
Methylprednisolone
The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Dulaglutide.
Methylprednisolone hemisuccinate
The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Dulaglutide.
Metolazone
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Metolazone.
Metoprolol
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Metoprolol.
Mifepristone
The risk or severity of hypoglycemia can be increased when Mifepristone is combined with Dulaglutide.
Miglitol
The risk or severity of hypoglycemia can be increased when Miglitol is combined with Dulaglutide.
Milnacipran
The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Dulaglutide.
Mometasone furoate
The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Dulaglutide.
Moxifloxacin
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Moxifloxacin.
Nadolol
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Nadolol.
Nateglinide
The risk or severity of hypoglycemia can be increased when Nateglinide is combined with Dulaglutide.
Nebivolol
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Nebivolol.
Nefazodone
The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Dulaglutide.
Nelfinavir
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Nelfinavir.
Niacin
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Niacin.
Nicardipine
The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Dulaglutide.
Nifedipine
The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Dulaglutide.
Nilotinib
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Nilotinib.
Nimodipine
The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Dulaglutide.
Nisoldipine
The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Dulaglutide.
Norethisterone
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Norethisterone.
Norgestimate
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Norgestimate.
Nortriptyline
Nortriptyline may decrease the hypoglycemic activities of Dulaglutide.
Octreotide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Octreotide.
Ofloxacin
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Ofloxacin.
Olanzapine
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Olanzapine.
Olsalazine
Olsalazine may increase the hypoglycemic activities of Dulaglutide.
Paliperidone
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Paliperidone.
Paroxetine
The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Dulaglutide.
Pasireotide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Pasireotide.
Pegvisomant
The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dulaglutide.
Pentamidine
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Pentamidine.
Phentermine
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Phentermine.
Phenytoin
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Phenytoin.
Pinaverium
The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Dulaglutide.
Pindolol
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Pindolol.
Pioglitazone
The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Dulaglutide.
Polythiazide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Polythiazide.
Pozelimab
The serum concentration of Pozelimab can be decreased when it is combined with Dulaglutide.
Pramlintide
The risk or severity of hypoglycemia can be increased when Pramlintide is combined with Dulaglutide.
Prednicarbate
The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Dulaglutide.
Prednisolone
The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Dulaglutide.
Prednisolone acetate
The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Dulaglutide.
Prednisolone phosphate
The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Dulaglutide.
Prednisone
The risk or severity of hyperglycemia can be increased when Prednisone is combined with Dulaglutide.
Pregabalin
The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Dulaglutide.
Progesterone
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Progesterone.
Propafenone
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Propafenone.
Propranolol
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Propranolol.
Protriptyline
Protriptyline may decrease the hypoglycemic activities of Dulaglutide.
Pseudoephedrine
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Pseudoephedrine.
Quetiapine
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Quetiapine.
Quinine
The risk or severity of hypoglycemia can be increased when Quinine is combined with Dulaglutide.
Repaglinide
The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Dulaglutide.
Risperidone
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Risperidone.
Ritonavir
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ritonavir.
Rosiglitazone
The risk or severity of hypoglycemia can be increased when Rosiglitazone is combined with Dulaglutide.
Salicylic acid
Salicylic acid may increase the hypoglycemic activities of Dulaglutide.
Saquinavir
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Saquinavir.
Saxagliptin
The risk or severity of hypoglycemia can be increased when Saxagliptin is combined with Dulaglutide.
Semaglutide
The risk or severity of hypoglycemia can be increased when Dulaglutide is combined with Semaglutide.
Sertraline
The risk or severity of hypoglycemia can be increased when Sertraline is combined with Dulaglutide.
Sirolimus
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Sirolimus.
Sitagliptin
The risk or severity of hypoglycemia can be increased when Sitagliptin is combined with Dulaglutide.
Somapacitan
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Somapacitan.
Somatotropin
Somatotropin may decrease the hypoglycemic activities of Dulaglutide.
Somatrogon
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Somatrogon.
Sotagliflozin
The risk or severity of hypoglycemia can be increased when Dulaglutide is combined with Sotagliflozin.
Sotalol
The risk or severity of hypoglycemia can be increased when Sotalol is combined with Dulaglutide.
Sulfadiazine
The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Dulaglutide.
Sulfamethoxazole
The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Dulaglutide.
Sulfasalazine
Sulfasalazine may increase the hypoglycemic activities of Dulaglutide.
Sunitinib
The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Dulaglutide.
Tacrolimus
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Tacrolimus.
Temsirolimus
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Temsirolimus.
Teprotumumab
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Teprotumumab.
Thyroid, porcine
Thyroid, porcine may decrease the hypoglycemic activities of Dulaglutide.
Thyrotropin alfa
Thyrotropin alfa may decrease the hypoglycemic activities of Dulaglutide.
Timolol
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Timolol.
Tipranavir
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Tipranavir.
Tirzepatide
The risk or severity of hypoglycemia can be increased when Dulaglutide is combined with Tirzepatide.
Tixocortol
The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Dulaglutide.
Tolazamide
Dulaglutide may increase the hypoglycemic activities of Tolazamide.
Torasemide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Torasemide.
Triamcinolone
The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Dulaglutide.
Trimipramine
Trimipramine may decrease the hypoglycemic activities of Dulaglutide.
Triptorelin
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Triptorelin.
Trolamine salicylate
Trolamine salicylate may increase the hypoglycemic activities of Dulaglutide.
Trovafloxacin
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Trovafloxacin.
Ubidecarenone
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Dulaglutide.
Ulobetasol
The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Dulaglutide.
Vamorolone
The risk or severity of hyperglycemia can be increased when Vamorolone is combined with Dulaglutide.
Venlafaxine
The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Dulaglutide.
Verapamil
The risk or severity of hypoglycemia can be increased when Verapamil is combined with Dulaglutide.
Vorinostat
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Vorinostat.
Xylometazoline
The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Dulaglutide.
Ziconotide
The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Dulaglutide.
Ziprasidone
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ziprasidone.
Zonisamide
The risk or severity of hypoglycemia can be increased when Zonisamide is combined with Dulaglutide.
Acetazolamide
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Acetazolamide.
Acetyl sulfisoxazole
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Acetyl sulfisoxazole.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Dulaglutide.
Aducanumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Aducanumab.
Albuterol
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Albuterol.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dulaglutide.
Alirocumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Alirocumab.
Amivantamab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Amivantamab.
Anifrolumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Anifrolumab.
Ansuvimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Ansuvimab.
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dulaglutide.
Asfotase alfa
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Asfotase alfa.
Atezolizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Atezolizumab.
Atoltivimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Atoltivimab.
Avelumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Avelumab.
Axatilimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Axatilimab.
Bamlanivimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Bamlanivimab.
Basiliximab
The risk or severity of adverse effects can be increased when Basiliximab is combined with Dulaglutide.
Belimumab
The risk or severity of adverse effects can be increased when Belimumab is combined with Dulaglutide.
Benralizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Benralizumab.
Bevacizumab
The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dulaglutide.
Bezlotoxumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Bezlotoxumab.
Bimekizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Bimekizumab.
Blinatumomab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Blinatumomab.
Bosentan
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Bosentan.
Brentuximab vedotin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dulaglutide.
Brodalumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Brodalumab.
Brolucizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Brolucizumab.
Burosumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Burosumab.
Canakinumab
The risk or severity of adverse effects can be increased when Canakinumab is combined with Dulaglutide.
Caplacizumab
The risk or severity of adverse effects can be increased when Caplacizumab is combined with Dulaglutide.
Celecoxib
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Celecoxib.
Cemiplimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Cemiplimab.
Certolizumab pegol
The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Dulaglutide.
Cetuximab
The risk or severity of adverse effects can be increased when Cetuximab is combined with Dulaglutide.
Cilgavimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Cilgavimab.
Crovalimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Crovalimab.
Daratumumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Daratumumab.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Dulaglutide.
Diclofenamide
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Diclofenamide.
Digoxin Immune Fab (Ovine)
The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dulaglutide.
Dinutuximab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Dinutuximab.
Donanemab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Donanemab.
Dostarlimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Dostarlimab.
Dupilumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Dupilumab.
Durvalumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Durvalumab.
Ebola Zaire vaccine (live, attenuated)
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Dulaglutide.
Eculizumab
The risk or severity of adverse effects can be increased when Eculizumab is combined with Dulaglutide.
Eflapegrastim
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Eflapegrastim.
Eftrenonacog alfa
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Eftrenonacog alfa.
Elotuzumab
The risk or severity of adverse effects can be increased when Elotuzumab is combined with Dulaglutide.
Emapalumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Emapalumab.
Emicizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Emicizumab.
Eptinezumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Eptinezumab.
Erenumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Erenumab.
Esterified estrogens
Esterified estrogens may increase the thrombogenic activities of Dulaglutide.
Estradiol acetate
Estradiol acetate may increase the thrombogenic activities of Dulaglutide.
Estradiol cypionate
Estradiol cypionate may increase the thrombogenic activities of Dulaglutide.
Estradiol valerate
Estradiol valerate may increase the thrombogenic activities of Dulaglutide.
Estriol
Estriol may increase the thrombogenic activities of Dulaglutide.
Evolocumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Evolocumab.
Fanolesomab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Fanolesomab.
Fedratinib
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Fedratinib.
Fluoxymesterone
Fluoxymesterone may increase the hypoglycemic activities of Dulaglutide.
Fremanezumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Fremanezumab.
Galcanezumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Galcanezumab.
Gemtuzumab ozogamicin
The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dulaglutide.
Glofitamab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Glofitamab.
Golimumab
The risk or severity of adverse effects can be increased when Golimumab is combined with Dulaglutide.
Guselkumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Guselkumab.
Hepatitis B immune globulin
The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Dulaglutide.
Human cytomegalovirus immune globulin
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Human cytomegalovirus immune globulin.
Human immunoglobulin G
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dulaglutide.
Human Rho(D) immune globulin
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Human Rho(D) immune globulin.
Human varicella-zoster immune globulin
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Human varicella-zoster immune globulin.
Ibalizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Ibalizumab.
Ibritumomab tiuxetan
The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dulaglutide.
Idarucizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Idarucizumab.
Inebilizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Inebilizumab.
Infliximab
The risk or severity of adverse effects can be increased when Infliximab is combined with Dulaglutide.
Inotuzumab ozogamicin
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Dulaglutide.
Ipilimumab
The risk or severity of adverse effects can be increased when Ipilimumab is combined with Dulaglutide.
Isatuximab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Isatuximab.
Isocarboxazid
Isocarboxazid may increase the hypoglycemic activities of Dulaglutide.
Ixekizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Ixekizumab.
Lanadelumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Lanadelumab.
Lebrikizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Lebrikizumab.
Lecanemab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Lecanemab.
Levothyroxine
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Levothyroxine.
Linezolid
Linezolid may increase the hypoglycemic activities of Dulaglutide.
Lithium carbonate
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lithium carbonate.
Loncastuximab tesirine
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Loncastuximab tesirine.
Maftivimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Maftivimab.
Margetuximab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Margetuximab.
Marstacimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Marstacimab.
Mepolizumab
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Dulaglutide.
Methazolamide
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Methazolamide.
Methylene blue
Methylene blue may increase the hypoglycemic activities of Dulaglutide.
Methyltestosterone
Methyltestosterone may increase the hypoglycemic activities of Dulaglutide.
Mirvetuximab soravtansine
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Mirvetuximab Soravtansine.
Mitapivat
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Mitapivat.
Mogamulizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Mogamulizumab.
Mosunetuzumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Mosunetuzumab.
Nandrolone decanoate
Nandrolone decanoate may increase the hypoglycemic activities of Dulaglutide.
Natalizumab
The risk or severity of adverse effects can be increased when Natalizumab is combined with Dulaglutide.
Necitumumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Necitumumab.
Nemolizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Nemolizumab.
Nipocalimab
The serum concentration of Dulaglutide can be decreased when it is combined with Nipocalimab.
Nivolumab
The risk or severity of adverse effects can be increased when Nivolumab is combined with Dulaglutide.
Obiltoxaximab
The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Dulaglutide.
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Dulaglutide.
Ocrelizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Ocrelizumab.
Odesivimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Odesivimab.
Ofatumumab
The risk or severity of adverse effects can be increased when Ofatumumab is combined with Dulaglutide.
Olaratumab
The risk or severity of adverse effects can be increased when Olaratumab is combined with Dulaglutide.
Omalizumab
The risk or severity of adverse effects can be increased when Omalizumab is combined with Dulaglutide.
Oxandrolone
Oxandrolone may increase the hypoglycemic activities of Dulaglutide.
Oxymetholone
Oxymetholone may increase the hypoglycemic activities of Dulaglutide.
Palivizumab
The risk or severity of adverse effects can be increased when Palivizumab is combined with Dulaglutide.
Panitumumab
The risk or severity of adverse effects can be increased when Panitumumab is combined with Dulaglutide.
Pembrolizumab
The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Dulaglutide.
Penpulimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Penpulimab.
Pertuzumab
The risk or severity of adverse effects can be increased when Pertuzumab is combined with Dulaglutide.
Phenelzine
Phenelzine may increase the hypoglycemic activities of Dulaglutide.
Polatuzumab vedotin
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Polatuzumab vedotin.
Probenecid
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Probenecid.
Procaine
Procaine may increase the hypoglycemic activities of Dulaglutide.
Procarbazine
Procarbazine may increase the hypoglycemic activities of Dulaglutide.
Ramucirumab
The risk or severity of adverse effects can be increased when Ramucirumab is combined with Dulaglutide.
Ranibizumab
The risk or severity of adverse effects can be increased when Ranibizumab is combined with Dulaglutide.
Rasagiline
Rasagiline may increase the hypoglycemic activities of Dulaglutide.
Ravulizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Ravulizumab.
Raxibacumab
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Dulaglutide.
Relatlimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Relatlimab.
Reslizumab
The risk or severity of adverse effects can be increased when Reslizumab is combined with Dulaglutide.
Risankizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Risankizumab.
Rituximab
The risk or severity of adverse effects can be increased when Rituximab is combined with Dulaglutide.
Romosozumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Romosozumab.
Rosuvastatin
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Rosuvastatin.
Rozanolixizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Rozanolixizumab.
Sacituzumab govitecan
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Sacituzumab govitecan.
Safinamide
Safinamide may increase the hypoglycemic activities of Dulaglutide.
Sarilumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Sarilumab.
Secukinumab
The risk or severity of adverse effects can be increased when Secukinumab is combined with Dulaglutide.
Selegiline
Selegiline may increase the hypoglycemic activities of Dulaglutide.
Siltuximab
The risk or severity of adverse effects can be increased when Siltuximab is combined with Dulaglutide.
Sotatercept
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Sotatercept.
Sotrovimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Sotrovimab.
Spesolimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Spesolimab.
Sulfamethizole
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Sulfamethizole.
Sumatriptan
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Sumatriptan.
Sutimlimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Sutimlimab.
Synthetic Conjugated Estrogens, A
Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Dulaglutide.
Synthetic Conjugated Estrogens, B
Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Dulaglutide.
Tafasitamab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Tafasitamab.
Tamsulosin
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Tamsulosin.
Telisotuzumab vedotin
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Telisotuzumab vedotin.
Teplizumab
The risk or severity of adverse effects can be increased when Teplizumab is combined with Dulaglutide.
Testosterone
Testosterone may increase the hypoglycemic activities of Dulaglutide.
Testosterone cypionate
Testosterone cypionate may increase the hypoglycemic activities of Dulaglutide.
Testosterone enanthate
Testosterone enanthate may increase the hypoglycemic activities of Dulaglutide.
Testosterone propionate
Testosterone propionate may increase the hypoglycemic activities of Dulaglutide.
Testosterone undecanoate
Testosterone undecanoate may increase the hypoglycemic activities of Dulaglutide.
Tetanus immune globulin, human
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Tetanus immune globulin, human.
Tezepelumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Tezepelumab.
Tildrakizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Tildrakizumab.
Tislelizumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Tislelizumab.
Tisotumab vedotin
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Tisotumab vedotin.
Tixagevimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Tixagevimab.
Tocilizumab
The risk or severity of adverse effects can be increased when Tocilizumab is combined with Dulaglutide.
Toripalimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Toripalimab.
Tralokinumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Tralokinumab.
Tranylcypromine
Tranylcypromine may increase the hypoglycemic activities of Dulaglutide.
Trastuzumab
The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dulaglutide.
Trastuzumab deruxtecan
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Trastuzumab deruxtecan.
Trastuzumab emtansine
The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Dulaglutide.
Tremelimumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Tremelimumab.
Ublituximab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Ublituximab.
Ustekinumab
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Dulaglutide.
Valdecoxib
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Valdecoxib.
Vedolizumab
The risk or severity of adverse effects can be increased when Vedolizumab is combined with Dulaglutide.
Vemurafenib
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Vemurafenib.
Vilobelimab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Vilobelimab.
Zanidatamab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Zanidatamab.
Zenocutuzumab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Zenocutuzumab.
Zolbetuximab
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Zolbetuximab.
